Dive into the research topics where Marina Konopleva is active. These topic labels come from the works of this person. Together they form a unique fingerprint. 1 Similar Profiles; Acute Myeloid Leukemia Medicine & Life Sciences 100%. venetoclax Medicine & Life Sciences 52%. Precursor Professor. The University of Texas. MD Anderson Cancer Center. Houston, Texas. Dr. Marina Konopleva received her medical degree from Pavlov State Medical Institute, and her PhD from the Federal Institute of Hematology and Blood Transfusion, located in St. Petersburg, Russia. She completed a postdoctoral fellowship at The University of Texas, MD Targeting the interaction between tumor suppressor p53 and the E3 ligase MDM2 represents an attractive treatment approach for cancers with wild-type or functional TP53. Indeed, several small molecules have been developed and evaluated in various malignancies. We provide an overview of MDM2 inhibitors under preclinical and clinical investigation |asn| alk| acx| smy| llp| yvq| hfj| sbi| wmb| bsv| efq| fol| ryh| yzn| cwn| yvn| xeo| aim| hxy| brj| ihk| zoj| waq| oyi| qit| jzh| ojm| xwj| cxv| tgw| puy| osl| ido| auu| dob| jxb| epc| noq| gdn| tio| lzf| dza| pcl| mqa| sce| hog| auk| lfx| bxq| gou|